Follow Whatsapp Channel
Saturday, Jun 21, 2025
The conclusion was reached after a study that evaluated a two-dose vaccination schedule of Moderna's Covid-19 vaccine candidate given in two age cohorts.
Moderna uses the 'mRNA' technology which means the vaccine is not embedded with the virus itself and therefore no risk of catching COVID-19 from the shot itself.
'We don't want to see situation where you are moving from a so-called lockdown state to bring the virus under control to moving to a so-called lockdown state,' a WHO official said.
The most common complaint was fatigue after the second vaccine dose, affecting about 4 per cent of the participants who got the shot.
To date, no mRNA vaccine has been licensed for infectious diseases and if an mRNA vaccine is approved for coronavirus, it would be the first of its type.
Unless some nasty surprises turn up, Pfizer's action on Friday could be the first step towards vaccinating the most vulnerable Americans by December end.
Russia became the first country to give regulatory approval to a COVID-19 vaccine in August when Sputnik V was officially registered ahead of large-scale clinical trial.
'The novel mutation will have implications for the diagnostic RT-PCR-based detection of the COVID-19 virus, which uses screening test.'
According to the researchers, two weeks after the second dose, more than 99 per cent of participants had neutralising antibody responses. These included people of all ages.
The study also identified the optimum dose to generate the highest antibody responses, while taking account of side effects and production capacity.
Results 301-310 of 325
You can always sign back in at any time.
You have reached the maximum number of saved items. Please remove some items.
